Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells

Hugh S. Gannon; Tao Zou; Michael K. Kiessling; Galen F. Gao; Diana Cai; Peter S. Choi; Alexandru P. Ivan; Ilana Buchumenski; Ashton C. Berger; Jonathan T. Goldstein; Andrew D. Cherniack; Francisca Vazquez; Aviad Tsherniak; Erez Y. Levanon; William C. Hahn; Matthew Meyerson

doi:10.1038/s41467-018-07824-4

Nature Communications (Dec 2018)

Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells

Hugh S. Gannon,
Tao Zou,
Michael K. Kiessling,
Galen F. Gao,
Diana Cai,
Peter S. Choi,
Alexandru P. Ivan,
Ilana Buchumenski,
Ashton C. Berger,
Jonathan T. Goldstein,
Andrew D. Cherniack,
Francisca Vazquez,
Aviad Tsherniak,
Erez Y. Levanon,
William C. Hahn,
Matthew Meyerson

Affiliations

Hugh S. Gannon: Department of Medical Oncology, Dana-Farber Cancer Institute
Tao Zou: Department of Medical Oncology, Dana-Farber Cancer Institute
Michael K. Kiessling: Department of Gastroenterology and Hepatology, University of Zurich and University Hospital Zürich
Galen F. Gao: Broad Institute of Harvard and MIT
Diana Cai: Department of Medical Oncology, Dana-Farber Cancer Institute
Peter S. Choi: Department of Medical Oncology, Dana-Farber Cancer Institute
Alexandru P. Ivan: Department of Medical Oncology, Dana-Farber Cancer Institute
Ilana Buchumenski: The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University
Ashton C. Berger: Broad Institute of Harvard and MIT
Jonathan T. Goldstein: Broad Institute of Harvard and MIT
Andrew D. Cherniack: Department of Medical Oncology, Dana-Farber Cancer Institute
Francisca Vazquez: Broad Institute of Harvard and MIT
Aviad Tsherniak: Broad Institute of Harvard and MIT
Erez Y. Levanon: The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University
William C. Hahn: Department of Medical Oncology, Dana-Farber Cancer Institute
Matthew Meyerson: Department of Medical Oncology, Dana-Farber Cancer Institute

DOI: https://doi.org/10.1038/s41467-018-07824-4
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 10

Abstract

Read online

Specific cancer cell vulnerabilities can provide an opportunity for the development of novel cancer therapeutics. In this study the authors demonstrate that targeting ADAR1 represents a potential therapeutic vulnerability in cancers with activated interferon response signatures.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal